research_top

研究業績

リンククリックで各業績の関連ページに別タブで遷移します。

2023年
  1. Hattori N, Yokoyama H, Takumi A, Kawaguchi S, Yamaguchi K, Shimazaki T, Shibui Y, Saito K, Saito Y.: Effect of microsampling (50 μL) on toxicological evaluation of methapyrilene, a hepatotoxic substance, in a collaborative 28-day study in female rats. J Toxcol. Sci., 2023; 48:1-14 (Jan).
  2. Adachi K, Ohyama K, Tanaka Y, Sato T, Murayama N, Shimizu M, Saito Y, Yamazaki H: High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4*16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database. Drug Metab Pharmacokinet. 2023 ; 49: 100486 (Apr).
  3. Nakamura R, Arakawa N, Tanaka Y, Uchiyama N, Sekine A, Mashimo Y, Tsuji K, Kagawa T, Sato K, Watanabe M, Aiso M, Hiasa Y, Takei Y, Ohira H, Ayada M, Tsukagoshi E, Maekawa K, Tohkin M, Saito Y, Takikawa H. Significant association between HLA-B*35:01 and onset of drug-induced liver injury caused by Kampo medicines in Japanese. Hepatol Res. 2023 ; 53: 440-449 (May) .
  4. Yamamoto N, Tanno Y, Tanaka Y, Hira D, Terada T, Saito Y, Yokozawa Y. Development of Novel Mass Spectrum-based Assay for Simultaneous Detection of 36 Variants in the 14 Pharmacogenetic Genes for the Japanese Population. Biol Pharm Bull. 2023; 46: 511-516 (Mar).
  5. Shibata H, Nishimura K, Saito Y, Ishii-Watabe A: Comparison of immunochemical reactions of infliximab innovator and biosimilars on an infliximab detecting kit used for therapeutic drug monitoring. Biol Pharm Bull. 2023; 46: 621-629 (Apr) .
  6. Tsukagoshi E, Nakamura R, Tanaka Y, Maekawa K, Hiratsuka M, Asada H, Saito Y. Validation of a genotyping technique for a surrogate marker of HLA-B*58:01 for allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in the Japanese population. Drug Metab Pharmacokinet. 2023 ;49:100495. (Apr).
  7. Tanaka Y, Takahashi K, Hattori N, Yokoyama H, Yamaguchi K, Shibui Y, Kawaguchi S, Shimazaki T, Nakai K, Kusuhara H, Saito Y. The influence of serial 50 μL microsampling on rats administered azathioprine, the immunosuppressive drug. Toxicol Rep. 2023; 10: 334-340 (Mar).
  8. Ishikawa R, Saito K, Tachiki H, Goda R, Arai K, Shimizu H, Andou T, Takahara K, Uchiyama H, Nitta S, Kakehi M, Hayashi K, Katagiri N, Kojima K, Fujita H, Tsuchinaga K, Saito Y: Multi-laboratory evaluation of immunoaffinity liquid chromatography-mass spectrometry-based glucagon-like peptide-1 assay. Bioanalysis, 2023 ;15: 207-218 (Feb).
  9. Adachi K, Ohyama K, Tanaka Y, Nakano H, Sato T, Murayama N, Shimizu M, Saito Y, Yamazaki H. Plasma and hepatic exposures of celecoxib and diclofenac prescribed alone in patients with cytochrome P450 2C9*3 modeled after virtual oral administrations and likely associated with adverse drug events reported in a Japanese database. Biol Pharm Bull. 2023, 46: 856-863 (Jun).
  10. Ishikawa R, Saito K, Misawa T, Demizu Y, Saito Y. Identification of the stapled α-helical peptide ATSP-7041 as a substrate and strong inhibitor of OATP1B1 in vitro. Biomolecule, in press.
  11. Takahashi K, Hattori N, Yokoyama H, Jinno F, Ohtsuka H, Nakai K, Takumi A, Shibui Y, Yamaguchi K, Shimazaki T, Tanaka Y, Saito K, Kobayashi A, Saito Y.: Impact of microsampling on toxicological evaluation in rodent safety studies. J Appl Toxicol. in press.
2022年
  1. Shibata H, Nishimura K, Maeda T, Honma M, Goda Y, Ishii-Watabe A, Saito Y. Evaluation of the analytical performance of anti-SARS-CoV-2 antibody test kits distributed or developed in Japan. Bioanalysis. 2022; 14: 325-340 (Mar).
  2. Yoshinari T, Hayashi K, Hirose S, Ohya K, Ohnishi T, Watanabe M, Taharaguchi S, Mekata H, Taniguchi T, Maeda T, Orihara Y, Kawamura R, Arai S, Saito Y, Goda Y, Hara-Kudo Y.: Matrix-Assisted Laser Desorption and Ionization Time-of-Flight Mass Spectrometry Analysis for the Direct Detection of SARS-CoV-2 in Nasopharyngeal Swabs. Anal Chem. 2022; 94: 4218-26 (Mar).
  3. 青木良子、佐井君江、勝田由紀子、鈴木美佳、鈴木康夫、石井明子、斎藤嘉朗: 本邦における抗体及び抗体関連医薬品のバイオシミラー採用及び処方に関する医師の意識調査. 薬学雑誌, 2022; 142: 547-560. (May).
  4. Ohtsuka H, Takahashi K, Kitaura H, Kandori H, Danbayashi K, Higuchi T, Jinno F, Nitta S, Mori K, Iwai A, Nakai K, Saito K, Saito Y.: No obvious toxicological influences of 50 μL microsampling from rats administered phenacetin as a drug with hematological toxicity. J Toxicol. Sci., 2022; 47:193-199. (May)
  5. Muta K, Saito K, Kemmochi Y, Masuyama T, Kobayashi A, Saito Y, Sugai S. Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide-induced hepatic steatosis in rats. J Appl Toxicol. 2022; 42: 1533-1547. (Sept)
  6. Arakawa N, Matsuyama S, Matsuoka M, Kitamura I, Miyashita K, Kitagawa Y, Imai K, Ogawa K, Maeda T, Saito Y, Hasegawa C. Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression. J Pharmacol Sci., 2022; 150: 21-30.(Sept)
  7. Saito K, Ishikawa R, Kitamura I, Ogawa K, Arakawa N, Sun Y, Imai K, Maeda T, Saito Y, Hasegawa C. Characterization of serotonin as a candidate biomarker of severity and prognosis of COVID-19 using LC/MS analysis. J Pharmacol Sci, 2022 , 50: 49-55. (Oct)
  8. Maeda K, Takikawa H, Aiso M, Kagawa T, Watanabe M, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Hashimoto E, Ayada M, Ikegami T, Arakawa N, Kusuhara H, Saito Y, Sugiyama Y: Frequency of null genotypes of glutathione S-transferase M1 and T1 in Japanese patients with drug-induced liver injury. Hepatol Res. 202, 52: 882-887. (Oct)
  9. Arakawa N, Ushiki A, Abe M, Matsuyama S, Saito Y, Kashiwada T, Horimasu Y, Gemma G, Tatsumi K, Hattori N, Tsushima K, Miyashita K, Saito K, Nakamura R, Toyoda T, Ogawa K, Sato M, Takamatsu K, Mori K, Nishiya T, Izumi T, Ohno Y, Saito Y and Hanaoka M: Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage. Nat Commun. 2022, 13: 5854. (Oct)
  10. Tanaka Y, Urayama KY, Mori M, Arakawa Y, Hasegawa D, Noguchi Y, Yanagimachi M, Keino D, Ota S, Akahane K, Inukai T, Hangai M, Kawaguchi T, Takagi M, Koh K, Matsuda F, Manabe A. Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2022; 199: 260-269. (Oct)
  11. Saito K, Gemma A, Tatsumi K, Hattori N, Ushiki A, Tsushima K, Saito Y, Abe M, Horimasu Y, Kashiwada T, Mori K, Sato M, Nishiya T, Takamatsu K, Sun Y, Arakawa N, Izumi T, Ohno Y, Saito Y, Hanaoka M.: Identification and characterization of lysophosphatidylcholine 14:0 as a biomarker for drug-induced lung disease. Sci. Rep. 2022, 12: 19819 (Nov).
  12. Minomo H, Inoue Y, Iwachido T, Oota H, Otabe K, Kubono K, Kondo S, Sasaki D, Suzuki Y, Nakamura Y, Naraoka H, Higashiyama M, Fujisawa N, Honda K, Matsumoto T, Yasui H, Saito Y, Toyota N.: Consideration for the Validation of Clinical Laboratory Method in Non-Clinical Fields. Bioanalysis, 2022 ; 14:1337-1348 (Nov).
  13. Sun Y, Nitta S, Saito K, Hosogai R, Nakai K, Goda R, Shimizu H, Fujita H, Masaaki Kakehi, Murata K, Yamaguchi T, Okuzono T, Yamane S, Kawabata M, Matsunuma T, Takahara K, Kato N, Yamada M, Yoshida T, Inoue T, Saito Y.: Development and multicenter validation of an LC/MS-based bioanalytical method for antisense therapeutics. Bioanalysis, 2022, 14, 1213-1227 (Dec).
  14. 中村亮介、荒川憲昭、斎藤嘉朗: 薬物性肝障害発症に関連するバイオマーカー. 医学のあゆみ 2022, 280(13) 1286-1291. (Mar)
  15. 田中庸一: 造血器腫瘍とpharmacogenomics. 臨床血液 2022, 63: 1353-1362. (Oct)
  16. 中村亮介、塚越絵里、斎藤嘉朗: HLA検査による重篤副作用の回避. 医学のあゆみ 2022, 283(7) 705-711. (Nov)
2021年
  1. Sai K, Nakatani E, Iwama Y, Hiraoka S, Tohkin M, Uyama Y, Saito Y. Efficacy comparison for a schizophrenia and a dysuria drug among East Asian populations: A retrospective analysis using multi-regional clinical trial data. Ther Innov Regul Sci, 2021; 55: 523-538. doi: 10.1007/s43441-020-00246-9. (May).
  2. Sato T, Cheng CL, Park HW, Kao Yang YH, Yang MS, Fujita M, Kumagai Y, Tohkin M, Saito Y, Sai K. Real world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study. Clin Transl Sci, 2021; 14: 1002-1014. doi: 10.1111/cts.12964. (May)
  3. Yamamoto E, Taquahashi Y, Kuwagata M, Saito H, Matsushita K, Toyoda T, Sato F, Kitajima S, Ogawa K, Izutsu KI, Saito Y, Hirabayashi Y, Iimura Y, Honma M, Okuda H, Goda Y. Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-μm aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging. Int J Pharm. 2021; 595: 120241.(Feb)
  4. Hashii N, Tousaka Y, Arai K, Enoki Y, Fukuda S, Goda R, Inoue N, Kawabata M, Murata K, Nakatsuji M, Okuzono T, Shigeyama T, Tachiki H, Yamaguchi T, Yamane S, Yamaoka M, Saito Y, Ishii-Watabe A. Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC-MS. Bioanalysis. 2021; 13: 265-276. (Feb)
  5. Tsukagoshi E, Tanaka Y, Saito Y. Implementation of pharmacogenomic information on Stevens-Johnson syndrome and toxic epidermal necrolysis. Front. Med., 2021; 8: 644154. (Mar)
  6. Imatoh T, Saito Y. Associations between Stevens-Johnson syndrome and infection: overview of pharmacoepidemiological studies. Front. Med., 2021; 8: 644871. (Mar)
  7. Saito K. Application of comprehensive lipidomics to biomarker research on adverse drug reactions. Drug Metab. Pharmacokinet. 2021; 37: 100377. doi: 10.1016/j.dmpk.2020.100377. (Apr).
  8. Saito K, Hattori K, Hidese S, Sasayama D, Miyakawa T, Matsumura R, Tatsumi M, Yokota Y, Ota M, Hori H, Kunugi H. Profiling of Cerebrospinal Fluid Lipids and Their Relationship with Plasma Lipids in Healthy Humans. Metabolites. 2021 Apr 24;11(5):268. doi: 10.3390/metabo11050268. (Apr)
  9. Sanoh S, Saito K. Omics analyses and their application for the discovery of biomarkers reflecting drug efficacy and adverse reaction. Drug Metab Pharmacokinet. 2021; 39: 100405. doi: 10.1016/j.dmpk.2021.100405. (Aug)
  10. Kimura A, Arakawa N, Kagawa H, Kimura Y, Hirano H. Phosphorylation of Ser1452 on BRG1 inhibits the function of the SWI/SNF complex in chromatin activation. J Proteomics. 2021 ; 247: 104319. doi: 10.1016/j.jprot.2021.104319. (Jul)
  11. Miyagi E, Arakawa N, Sakamaki K, Yokota NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y, Kasamatsu Y, Kato H, Mogami T, Miyagi Y, Kobayashi H. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary. Int J Clin Oncol. 2021; 26: 1336-1344. doi: 10.1007/s10147-021-01914-y. (Jul)
  12. Tsuji D, Saito Y, Mushiroda T, Miura M, Hira D, Terada T.: Results of a national survey of Japanese pharmacists in relation to the application of pharmacogenomic testing for precision medicine. J Clin Pharm Ther. 2021; 46: 649-657. doi: 10.1111/jcpt.13367. (Jun).
  13. Tanaka Y, Yeoh AEJ, Moriyama T, Li CK, Kudo K, Arakawa Y, Buaboonnam J, Zhang H, Liu HC, Ariffin H, Chen Z, Kham SKY, Nishii R, Hasegawa D, Fujimura J, Keino D, Kondoh K, Sato A, Ueda T, Yamamoto M, Taneyama Y, Hino M, Takagi M, Ohara A, Ito E, Koh K, Hori H, Manabe A, Yang JJ, Kato M. An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia. Haematologica. 2021; 106: 2026-2029. doi: 10.3324/haematol.2020.266320. (Jul)
  14. Imai K, Matsuoka M, Tabata S, Kitagawa Y, Nagura-Ikeda M, Kubota K, Fukada A, Takada T, Sato M, Noguchi S, Takeuchi S, Arakawa N, Miyoshi K, Saito Y, Maeda T. Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severity. Int J Infect Dis. 2021 15: S1201-9712(21)00659-7. doi: 10.1016/j.ijid.2021.08.026. (Aug)
  15. Tanaka Y, Saito Y. Importance of NUDT15 Polymorphisms in Thiopurine Treatments. J Pers Med. 2021; 11: 778. doi: 10.3390/jpm11080778. (Aug)
  16. Ohtsu Y, Tanaka S, Igarashi H, Kakehi M, Mori T, Nakamura T, Ohashi R, Shimizu H, Yasuda Y, Okayama T, Kakuo H, Yokoi H, Horiuchi M, Katashima M, Nakamura R, Saito K, Saito Y: Analytical Method Validation for Biomarkers as a Drug Development Tool: Points to Consider Bioanalysis, 2021; 13:1379-1389. doi: 10.4155/bio-2021-0173. (Sep).
  17. Ishikawa R, Saito K, Matsumura T, Arai K, Yamauchi S, Goda R, Tachiki H, Kawabata M, Nitta SI, Nagao A, Suga T, Uchiyama H, Nakai K, Asahina K, Yamaoka M, Saito Y., A multi-laboratory validation study of LC/MS biomarker assays for three lysophosphatidylcholines. Bioanalysis. 2021;13:1533-1546. doi: 10.4155/bio-2021-0150. (Oct)
  18. Solon E, Groseclose MR, Ho S, Tanaka K, Nakada N, Linehan S, Nishidate M, Yokoi H, Kaji H, Urasaki Y, Watanabe K, Ishida T, Komatsu R, Yoshida K, Yamazaki H, Saito K, Saito Y, Tanaka Y. Imaging Mass Spectrometry (IMS) for Drug Discovery and Development Survey: Results on Methods, Applications and Regulatory Compliance. Drug Metab. Pharmacokinet. 2021; 43:100438 (Dec).
  19. Maekawa K, Yamamura M, Ishikawa T, Matsuki A, Yajima K, Kosugi S, Saito Y, Kanda T, Hatakeyama K. Impacts of SNPs on Adverse Events and Trough Concentration of Imatinib in Patients with Gastrointestinal Stromal Tumors. Drug Metab. Pharmacokinet. 2021; 43: 100441 (Dec).
  20. 斎藤嘉朗、田中庸一、齊藤公亮: マイクロサンプリングの毒性評価への利用について. 毒性質問箱, 2021; 23: 32-36. (Sept)
2020年
  1. Nakamura R, Ozeki T, Hirayama N, Sekine A, Yamashita T, Yoichi Mashimo, Mizukawa Y, Shiohara T, Watanabe H, Sueki H, Ogawa K, Asada H, Kaniwa N, Tsukagoshi E, Matsunaga K, Niihara H, Yamaguchi Y, Aihara M, Mushiroda T, Saito Y, Morita E. Association of HLA-A*11:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients. J Invest Dermatol. 2020; 140: 1659-1662.e6. (Aug)
  2. Tohkin M, Saito Y, Yagi S, Asano K, Maekawa K, Osabe M, Iida S, Miyata N.: Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documents. Drug Metab Pharmacokinet. , 2020; 35; 187-190.(Apr)
  3. Imatoh T, Sai K, Saito Y.: The association between concurrence of infection and the onset of severe eruption or liver injury in patients using antipyretic analgesics: a matched-nested case-control study. J. Clin. Pharmacol. 2020; 60: 1177-1184. (Sept)
  4. Saito K, Hattori K, Andou T, Satomi Y, Gotou M, Kobayashi H, Hidese S, Kunugi H.: Characterization of Postprandial Effects on CSF Metabolomics: A Pilot Study with Parallel Comparison to Plasma. Metabolites. 2020; 10: 185 (May).
  5. Yokoyama H, Hattori N, Ohtsuka H, Murata E, Kobayashi A, Muta K, Takumi A, Kitaura H, Jinno F, Iwai A, Nakai K, Mori K, Saito K, Saito Y.: Lack of toxicological influences by microsampling (50 µl) from jugular vein of rats in a collaborative 28-day study. J Toxicol. Sci., 2020; 45, 319-325 (June).
  6. Imatoh T, Ushiki A, Ota M, Ito M, Sekine A, Yamashita T, Mashimo Y, Nakamura R, Saito K, Saito Y, Hanaoka M, Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population. Pharmacogenomics J, 2020; 20: 823-830. (Dec).
  7. Maeda M, Tanaka R, Aso M, Sakamoto Y, Song I, Ochiai M, Saito Y, Maekawa K, Arakawa N, Ohno Y, Kumagai Y: Hepatic Adaptation to Therapeutic Doses of acetaminophen: An Exploratory Study in healthy Individuals. Clin Ther, 2020; 42: 1276-91 (July).
  8. Hattori N, Takumi A, Saito K, Saito Y. Effects of serial cervical or tail blood sampling on toxicity and toxicokinetic evaluation in rats. J Toxicol. Sci., 2020; 45, 599-609 (Oct).
  9. Saito K, Kagawa T, Tsuji K, Kumagai Y, Sato K, Sakisaka S, Sakamoto N, Aiso M, Hirose S, Mori N, Tanaka R, Uraoka T, Takata K, Ogawa K, Mori K, Sato M, Nishiya T, Takamatsu K, Arakawa N, Izumi T, Ohno Y, Saito Y, Takikawa H. Plasma lipid profiling of three types of drug-induced liver injury in Japanese patients: A preliminary study. Metabolites, 2020; 10: 355. (Aug).
  10. Sun Y, Nitta SI, Saito K, Hosogai R, Nakai K, Goda R, Kakehi M, Murata K, Yamaguchi T, Okuzono T, Yamane S, Enoki Y, Kawabata M, Takahara K, Sato S, Yoshida T, Inoue T, Saito Y.: Development of a bioanalytical method for an antisense therapeutic using high-resolution mass spectrometry. Bioanalysis, 2020; 12: 1739-1756.(Dec)
  11. 辻大樹，斎藤嘉朗，莚田泰誠， 三浦昌朋，平 大樹，寺田智祐. 薬学的視点に基づいたプレシジョン・メディシンの国内基盤構築のための調査研究. 医療薬学 2020; 46: 66-76. (Feb)
  12. 田中庸一，塚越絵里，斎藤嘉朗. 精神科関連医薬品の副作用バイオマーカー. 精神科, 2020; .37, 634-641. (Dec)
2019年
  1. Wang YH, Chen CB, Tassaneeyakul W, Saito Y, Aihara M, Choon SE, Lee HY, Chang MM, Roa FD, Wu CW, Zhang J, Nakkam N, Konyoung P, Okamoto-Uchida Y, Man-Tung Cheung C, Huang JW, Ji C, Cheng B, Chung-Yee Hui R, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Ho HC, Lin JY, Yang CH, Chang YC, Su SC, Wang CW, Chung WH; Asian Severe Cutaneous Adverse Reaction Consortium. The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison to the USA FDA Label. Clin Pharmacol Ther. 2019;105:112-120.. (Jan)
  2. Imatoh T, Sai K, Takeyama M, Hori K, Karayama M, Furuhashi K, Segawa K, Kimura M, Kawakami J, Saito Y: Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia. J Clin Pharm Ther, 2019; 44: 62-68. (Feb)
  3. Su SC, Chen CB, Chang WC, Wang CW, Fan WL, Lu LY, Nakamura R, Saito Y, Ueta M, Kinoshita S, Sukasem C, Yampayon K, Kijsanayotin P, Nakkam N, Saksit N,Tassaneeyakul W, Aihara M, Lin YJ, Chang CJ, Wu T, Hung SI, Chung WH: HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians. Clin. Pharmacol. Ther., 2019;105: 476-485. (Feb)
  4. Okiyama Y, Watanabe C, Fukuzawa K, Mochizuki Y, Nakano T, Tanaka S.: Fragment Molecular Orbital Calculations with Implicit Solvent Based on the Poisson-Boltzmann Equation: II. Protein and Its Ligand-Binding System Studies. J Phys Chem B. 2019; 123: 957-973. (Feb)
  5. Nishimura K, Shibata H, Aoyama M, Hosogi J, Kadotsuji K, Minoura K, Mori T, Nakamura T, Nishimiya K, Nomura T, Saito T, Soma M, Wakabayashi H, Sakamoto N, Niimi S, Katori N, Saito Y, Ishii-Watabe A.: Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study. Bioanalysis. 2019;11: 509-524. (Mar)
  6. Ohtsu1 Y, Matsumaru T, Katashima M, Kakehi M, Kakuo H, Suzuki T, Mabuchi M, Nakamura R, Nakamura T, Katori N, Tanaka S, Saito Y: Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan. Bioanalysis, 2019; 11: 55-60. (Jan).
  7. Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA: Conference report: pharmacogenomics in special populations at WCP2018. Br J Clin Pharmacol. 2019;85: 467-475. (Mar)
  8. Saito K, Tanaka N, Ikari J, Suzuki M, Anazawa R, Abe M, Saito Y, Tatsumi K.: Comprehensive lipid profiling of bleomycin-induced lung injury.J Appl Toxicol. 2019;39: 658-671. (Apr)
  9. Sai K, Yoshida A, Hanatani T, Imatoh T, Takeuchi M, Narukawa M, Watanabe H, Uyama Y, Saito Y.: Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials. Br J Clin Pharmacol. 2019; 85: 1270-1282. (Jun)
  10. Sun Y, Saito K, Iiji R, Saito Y: Application of ion chromatography coupled with mass spectrometry for human serum and urine metabolomics. SLAS Discov, 2019; 24: 778-786. (Aug)
  11. Imatoh T, Sai K, Takeyama M, Segawa K, Yamashita T, Nakashima N, Kataoka, Y, Yokoi H, Hiramatsu T, Ohe K, Kimura M, Hori K, Kawakami J, Saito Y.: Evaluating the impact of regulatory action on denosumab-induced hypocalcemia in Japan. J Clin Pharm Ther, 2019; 44: 788-795. (Oct)
  12. Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S. Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma. Cancer Sci. 2019;110:3267-3274 (Oct).
  13. Saito K, Ueno S, Nakayama A, Nitta SI, Arai K, Hasunuma T, Saito Y .Overall similarities and a possible factor affecting plasma metabolome profiles between venous and capillary blood samples from 20 healthy human males. J Pharm Sci. 2019; 108: 3737-3744 (Nov).
  14. Ueta M, Nakamura R, Saito Y, Tokunaga K, Sotozono C, Yabe T, Aihara M, Mastunaga K, Kinoshita S. Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. Hum Genome Var. 2019; 6: 50 (Oct).
  15. Saito K, Yagi H, Maekawa K, Nishigori M, Ishikawa M, Muto S, Osaki T, Iba Y, Minatoya K, Ikeda Y, Ishibashi-Ueda H, Ogino H, Sasaki H, Matsuda H, Saito Y, Minamino N.: Lipidomic signatures of aortic media from patients with atherosclerotic and nonatherosclerotic aneurysms. Sci Rep. 2019; 9: 15472 (Oct).
  16. Sun Y, Saito K, Saito Y.: Lipid Profile Characterization and Lipoprotein Comparison of Extracellular Vesicles from Human Plasma and Serum. Metabolites. 2019; 9. pii: E259 (Nov).
  17. 斎藤嘉朗, 青木良子, 荒川憲昭. ゲノム情報に基づいた副作用予測. 日本臨牀 2019; 77(増刊号3): 18-24. (Jul)
  18. 斎藤嘉朗, 中村亮介: 重症薬疹の発症機序と新規治療戦略. 薬学雑誌 2019; 139: 1557-1562. (Dec).
2018年
  1. Okamoto-Uchida Y, Nakamura R, Matsunaga K, Aihara M, Saito Y. Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements. Pharmacogenet Genomics. 2018; 28; 95-98. (Mar)
  2. Shibata H, Nishimura K, Miyama C, Tada M, Suzuki T, Saito Y, Ishii-Watabe A. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. J Immunol Methods. 2018; 452:73-77. (Jan)
  3. Ishii-Watabe A, Shibata H, Nishimura K, Hosogi J, Aoyama M, Nishimiya K, Saito Y. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan. Bioanalysis. 2018; 10; 95-105. (Jan)
  4. Okiyama Y, Nakano T, Watanabe C, Fukuzawa K, Mochizuki Y, Tanaka S.: Fragment Molecular Orbital Calculations with Implicit Solvent Based on the Poisson-Boltzmann Equation: Implementation and DNA Study. J Phys Chem B. 2018; ;122(16):4457-4471. (Apr)
  5. Mushiroda T, Takahashi Y, Onuma T, Yamamoto Y, Kamei T, Hoshida T, Takeuchi K, Otsuka K, Okazaki M, Watanabe M, Kanemoto K, Oshima T, Watanabe A, Minami S, Saito K, Tanii H, Shimo Y, Hara M, Saitoh S, Kinoshita T, Kato M, Yamada N, Akamatsu N, Fukuchi T, Ishida S, Yasumoto S, Takahashi A, Ozeki T, Furuta T, Saito Y, Izumida N, Kano Y, Shiohara T, Kubo M; GENCAT Study Group. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. JAMA Neurol. 2018; 75: 842-849. (Jul)
  6. Hiratsuka M, Hirasawa N, Oshima Y, Kodama S, Miyata T, Dan T, Takatoku H, Kuribayashi H, Nakamura R, Saito Y.: Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population. Drug Metab Pharmacokinet. 2018; 33: 141-149. (Jun)
  7. Imatoh T, Sai K, Saito Y.: Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions. J Clin Pharm Ther.2018;43:493-499. (Aug)
  8. Goda K, Saito K, Muta K, Kobayashi A, Saito Y, Sugai S. Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis. 2018; J Toxicol Sci. 43:395-405. (Jun)
  9. Saito Y, Katori N, Ohtsu Y: Current situation on biomarker validation in Japan. Bioanalysis, 10:901-903, 2018. (Jun)
  10. Saito K, Ikeda M, Kojima Y, Hosoi H, Saito Y, Kondo S: Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rate and hand-foot skin reaction of sorafenib-treated patients. Cancer Chemother Pharmacol, 2018; 82: 677-684. (Oct)
  11. Aoki H, Ito N, Kaniwa N, Saito Y, Wada Y, Nakajima K, Sago H, Murashima A, Okamoto A, Ito S: Low levels of amlodipine in breast milk and plasma. Breastfeed. Med., 2018;13: 622-626. (Nov)
  12. Sharma A, Saito Y, Hung SI, Naisbitt D, Uetrecht J, Bussiere J: The Skin as a Metabolic and Immune-Competent Organ: Implications for Drug-Induced Skin Rash. J. Immunotoxicol., 2018; 14: 1-12. (Oct)
  13. 熊谷雄治, 麻生雅子, 小田切圭一, 斎藤嘉朗, 富安里江, 蓮沼智子, 廣瀬誠： ヒト初回投与試験（FIH試験）を含む早期臨床試験のチェックリスト. 臨床薬理, 49: 183-194, 2018.
  14. 斎藤嘉朗: 健康食品に関する現状と医薬品との相互作用、有害事象事例. 薬学雑誌, 2018; 138: 1511-1516. (Dec)
2017年
  1. Imatoh T, Sai K, Hori K, Segawa K, Kawakami J, Kimura M, Saito Y: Development of a novel algorithm for detecting glucocorticoid-induced diabetes mellitus using a medical information database. J. Clin Pharm Ther., 42: 215-220, 2017.
  2. Saito K, Goda K, Kobayashi A, Yamada N, Maekawa K, Saito Y, Sugaia K: Arachidonic acid-containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen-induced hepatic phospholipidosis. J Appl Toxicol. 37: 943-953, 2017.
  3. 斎藤嘉朗、宇山佳明、佐井君江、頭金正博: 国際共同治験の現状と東アジア治験の推進のための民族差研究. レギュラトリーサイエンス学会誌. 7: 61-69, 2017.
  4. Goda K, Kobayashi A, Takahashi A, Takahashi T, Saito K, Maekawa K, Saito Y, Sugai S.Evaluation of the potential risk of drugs to induce hepatotoxicity in human—relationships between hepatic steatosis observed in non-clinical toxicity study and hepatotoxicity in humans. Int. J. Mol. Sci., 18: 810, 2017.
  5. Saito K, Ohno Y, Saito Y. Enrichment of resolving power improves ion-peak quantification on a lipidomics platform. J Chromatogr. B, 1055-1056: 20-28, 2017.
  6. Maekawa K, Okemoto K, Ishikawa M, Tanaka R, Kumagai Y, Saito Y: Plasma Lipidomics of Healthy Japanese Adults Reveals Gender- and Age-Related Differences. J Pharm Sci. 106: 2914-2918, 2017.
  7. Okamoto-Uchida Y, Nakamura R, Sai K, Imatoh T, Matsunaga K, Aihara M, Saito Y: Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Biol. Pharm. Bull. 40: 1576-1580, 2017.
  8. Takeyama M, Sai K, Imatoh T, Segawa K, Hirasawa N, Saito Y.: Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database. Biol. Pharm. Bull. 40: 1447-1453, 2017.
  9. Imatoh T, Sai K, Fukazawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y.: Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol. 73:1643-1653 (2017).
  10. Song I, Tanaka R, Aso M, Sakamoto Y, Maeda M, Ochiai M, Saito Y, Maekawa K, Kumagai Y.: Influences of long-term, high-dose acetaminophen administration on liver function markers in healthy Japanese adults. Jpn J Clin Pharmacol Ther, in press.
  11. Maekawa K, Adachi M, Matsuzawa Y, Zhang Q, Kuroki R, Saito Y, Shah MB.: Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. Biochemistry. 56: 5476-5480, 2017.
  12. Aoyama T, Ishida Y, Kaneko M, Miyamoto A, Saito Y, Tohkin M, Kawai S, Matsumoto Y. Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response. CPT Pharmacometrics Syst Pharmacol. 6; 823-832, 2017.
2016年
  1. Saito Y, Stamp LK, Caudle KE, Hershfield M, McDonagh EM, Callagham JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MTM: Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin. Pharmacol. Ther., 99: 36-7, 2016.
  2. Ishikawa M, Saito K, Yamada H, Nakatsu N, Maekawa K, Saito Y: Plasma lipid profiling of different types of hepatic fibrosis induced by carbon tetrachloride and lomustine in rats. Lipids Health Dis. 15: 74, 2016.
  3. Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S.: Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol. 81:1078-90, 2016.
  4. Nishimura M, Toyoda M, Takenaka K, Imamura Y, Chayahara N, Kiyota N, Mukohara T, Kotake T, Tsuji A, Saito K, Saito Y, Minami H.: The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 77:1165-70, 2016.
  5. Saito K, Maekawa K, Kinchen JM, Tanaka R, Kumagai Y, Saito Y: Gender- and age-associated differences in serum metabolite profiles among Japanese populations. Biol. Pharm. Bull. 39: 1179-86, 2016 (Selected as featured article) .
  6. Saito K, Arai E, Maekawa K, Ishikawa M, Fujimoto H, Taguchi R, Matsumoto K, Kanai Y, Saito Y.: Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma. Sci Rep. 6: 28932, 2016.
  7. Okamoto-Uchida Y, Nakamura R, Matsuzawa Y, Soma M, Kawakami H, Ishii-Watabe A, Nishimaki-Mogami T, Teshima R, Saito Y.: Different results of IgE binding- and crosslinking-based allergy tests caused by allergen immobilization. Biol. Pharm. Bull. 39:1662-1666, 2016.
  8. Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, Takeda K, Tanimoto T, Yamano T, Akasaka T, Ishida T, Hirata KI, Saku K, Yagi S, Soeki T, Sata M, Ueno M, Miyazaki S, Shiraki A, Oyama JI, Node K, Sugamura K, Ogawa H, Kurose K, Maekawa K, Matsuzawa Y, Imatoh T, Hasegawa R; Japanese Pharmacogenomics Data Science Consortium., Saito Y.: A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab. Pharmacokinet. 31: 467-470, 2016.
  9. Okamoto-Uchida Y, Yu R, Miyamura N, Arima N, Ishigami-Yuasa M, Kagechika H, Yoshida S, Hosoya T, Nawa M, Kasama T, Asaoka Y, Alois RW, Elling U, Penninger JM, Nishina S, Azuma N, Nishina H.: The mevalonate pathway regulates primitive streak formation via protein farnesylation. Sci Rep. 6:37697, 2016.
  10. Saito K, Ueta M, Maekawa K, Sotozono C, Kinoshita S, Saito Y.: Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. PLoS One. 11:e0167402, 2016.
  11. Okemoto K, Maekawa K, Tajima Y, Tohkin M, Saito Y.: Cross-Classification of Human Urinary Lipidome by Sex, Age, and Body Mass Index. PLoS One.; 11:e0168188, 2016.
2015年
  1. Ueta M, Sawai H, Sotozono C, Hitomi Y, Kaniwa N, Kim MK, Seo KY, Yoon KC, Joo CK, Kannabiran C, Wakamatsu TH, Sangwan V, Rathi V, Basu S, Ozeki T, Mushiroda T, Sugiyama E, Maekawa K, Nakamura R, Aihara M, Matsunaga K, Sekine A, Pereira Gomes JÁ, Hamuro J,Saito Y, Kubo M, Kinoshita S, Tokunaga K.: IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol., 135: 1538-1545, 2015.
  2. Furihata T, Kawamatsu S, Ito R, Saito K, Suzuki S, Kishida S, Saito Y, Kamiichi A, Chiba K.: Hydrocortisone enhances the barrier properties of HBMEC/ciβ, a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids Barriers CNS.; 12: 7, 2015.
  3. Kagawa T, Hirose S, Arase Y, Oka A, Anzai K, Tsuruya K, Shiraishi K, Orii R, Ieda S, Nakazawa T, Tomita K, Hokari R, Miura S, Ebinuma H, Saito H, Kitamura T, Horie Y, Okuse C, Wasada M, Inoko H, Tohkin M, Saito Y, Maekawa K, Takikawa H, Mine T.: No Contribution of the ABCB11 p.444A Polymorphism in Japanese Patients with Drug-induced Cholestasis. Drug Metab Dispos. 43: 691-697, 2015.
  4. Hanatani T, Sai K, Tohkin M, Segawa K, Saito Y: Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. Int J Clin Pharm., 37: 537-545, 2015.
  5. Saito K, Uebanso T, Maekawa K, Ishikawa M, Taguchi R, Nammo T, Nishimaki-Mogami T, Udagawa H, Fujii M, Shibazaki Y, Yoneyama H, Yasuda K, Saito Y.:Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis. Sci Rep. 5: 12466, 2015.
  6. Ishikawa M, Saito K, Urata M, Kumagai Y, Maekawa K, Saito Y.: Comparison of circulating lipid profiles between fasting humans and three animal species used in preclinical studies: mice, rats and rabbits. Lipids Health Dis. 14: 104, 2015.
  7. Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Doi T, Takahashi A, Odaka Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T.: Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. BMC Cancer, 15: 718, 2015.
  8. Maekawa K, Nakamura R, Kaniwa N, Mizusawa S, Kitamoto A, Kitamoto T, Ukaji M, Matsuzawa Y, Sugiyama E, Uchida Y, Kurose K, Ueta M, Chie Sotozono C, Ikeda H, Yagami A, Matsukura S, Kinoshita S, Muramatsu M, Ikezawa Z, Sekine A, Furuya H, Takahashi Y, Matsunaga K, Aihara M, Yoshiro Saito Y, Japan Pharmacogenomics Data Science Consortium: Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese. Pharmacogenomics, 16: 1689-1699, 2015.
  9. Kaniwa N, Ueta M, Nakamura R, Okamoto-Uchida Y, Sugiyama E, Maekawa K, Takahashi Y, Furuya H, Yagami A, Matsukura S, Ikezawa Z, Matsunaga K, Sotozono C, Aihara M, Kinoshita S, Saito Y.: Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. Allergol Int. 64: 379-381, 2015.
  10. Falcone FH, Alcocer MJ, Okamoto-Uchida Y, Nakamura R.: Use of humanized rat basophilic leukemia reporter cell lines as a diagnostic tool for detection of allergen-specific IgE in allergic patients: time for a reappraisal? Curr Allergy Asthma Rep. 15: 67, 2015.
  11. 斎藤嘉朗, 児玉進, 杉山永見子, 中村亮介： 重篤副作用に関する予測ゲノムマーカー, 薬学雑誌, 135: 589-595, 2015.
  12. 斎藤嘉朗、頭金正博：医薬品開発・適正使用におけるバイオマーカー利用とレギュラトリーサイエンス. 薬学雑誌, 135: 647-648, 2015.
  13. 頭金正博、斎藤嘉朗：バイオマーカーの適格性評価を支えるレギュラトリーサイエンス（オーバービュー）. 薬学雑誌, 135: 649-653, 2015.
2014年
  1. Sai K, Kurose K, Koizumi T, Katori N, Sawada J, Matsumura Y, Saijo N, Yamamoto N, Tamura T, Okuda H, Saito Y.: Distal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses. Biol. Pharm. Bull., 37: 164-168, 2014.
  2. Knights J, Sato Y, Kaniwa N, Saito Y, Ueno H, Ramanathan M.: Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity. Pharmacogenet. Genomics, 24: 15-25, 2014.
  3. Saito K, Maekawa K, Pappan KL, Urata M, Ishikawa M, Kumagai Y, Saito Y.: Differences in metabolite profiles between blood matrices, ages, and sexes among Caucasian individuals and their inter-individual variations. Metabolomics, in press.
  4. Hanatani T, Sai K, Tohkin M, Segawa K, Kimura M, Hori K, Kawakami J, Saito Y.: A detection algorithm for drug-induced liver injury in medical information databases using the diagnostic scale in Japan as compared to the CIOMS/RUCAM scale. Pharmacoepidemiol. Drug Safety, in press.
  5. Hanatani T, Sai K, Tohkin M, Segawa K, Antoku Y, Nakashima N, Yokoi H, Ohe K, Kimura M, Hori K, Kawakami J, Saito Y.: Evaluation of two Japanese regulatory actions using medical information databases: a “Dear Doctor” letter to restrict oseltamivir use in teenagers, and label change caution against co-admistration of omeprazole with clopidogrel. J. Clin. Pharm. Ther., 39: 361-367, 2014.
  6. Ishikawa M, Maekawa K, Saito K, Senoo Y, Urata M, Murayama M, Tajima Y, Kumagai Y, Saito Y.: Plasma and serum lipidomics of healthy white adults shows characteristic profiles by subjects' gender and age. PLoS One. 9: e91806, 2014.
  7. Ueta M, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H, Miyadera H, Sugiyama E, Maekawa K, Nakamura R, Nagato M, Aihara M, Matsunaga K, Takahashi Y, Furuya H, Muramatsu M, Ikezawa Z, Kinoshita S.: Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep. 4: 4862, 2014.
  8. Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, Chen MJ, Lin JY, Hui RC, Ho JC, Wu WM, Chen TJ, Wu T, Wu YR, Hsih MS, Tu PH, Chang CN, Hsu CN, Wu TL, Choon SE, Hsu CK, Chen DY, Liu CS, Lin CY, Kaniwa N, Saito Y, Takahashi Y, Nakamura R, Azukizawa H, Shi Y, Wang TH, Chuang SS, Tsai SF, Chang CJ, Chang YS, Hung SI; Taiwan Severe Cutaneous Adverse Reaction Consortium; Japan Pharmacogenomics Data Science Consortium.: Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 312: 525-534 (2014).
  9. Saito K, Maekawa K, Ishikawa M, Senoo Y, Urata M, Murayama M, Nakatsu N, Yamada H, Saito Y: Glucosylceramide and Glysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis. Toxicol. Sci., 141: 377-386, 2014.
  10. Saito K, Ishikawa M, Murayama M, Urata M, Senoo Y, Toyoshima K, Kumagai Y, Maekawa K, Saito Y.: Effects of sex, age, and fasting conditions on plasma lipidomic profiles of fasted Sprague-Dawley rats. PLoS One. 9: e112266, 2014.
  11. 前川京子, 斎藤嘉朗: 薬物性肝障害の遺伝的素因－ゲノムバイオマーカーを用いた発症予測の可能性. 医学のあゆみ, 248: 11-18, 2014.
  12. 斎藤嘉朗、前川京子、大野泰雄: 薬物相互作用に関する新ガイドライン案. レギュラトリーサイエンス学会誌, 4: 249-255, 2014.
  13. 斎藤嘉朗、中村亮介、前川京子： バイオマーカーに関する大学とのレギュラトリーサイエンス連携事業, 国立医薬品食品衛生研究所報告, 132: 19-21, 2014.
2013年
  1. Ishikawa M, Tajima Y, Murayama M, Senoo Y, Maekawa K, Saito Y.: Plasma and serum from nonfasting men and women differ in their lipidomic profiles. Biol Pharm Bull. 36: 682-685 (2013).
  2. Sai K, Hanatani T, Azuma Y, Segawa K, Tohkin M, Omatsu H, Makimoto H, Hirai M, Saito Y.: Development of a detection algorithm for statin-induced myopathy using electronic medical records. J Clin Pharm Ther. 38: 230-235 (2013).
  3. Kaniwa N, Saito Y.:Pharmacogenomics of severe cutaneous adverse reactions. Pharmacogenomics. 14: 595-598 (2013).
  4. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z.: A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 13: :60-69 (2013).
  5. Maekawa K, Hirayama A, Iwata Y, Tajima Y, Nishimaki-Mogami T, Sugawara S, Ueno N, Abe H, Ishikawa M, Murayama M, Matsuzawa Y, Nakanishi H, Ikeda K, Arita M, Taguchi R, Minamino N, Wakabayashi S, Soga T, Saito Y.: Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J. Mol. Cell. Cardiol., 59: 76-85, 2013.
  6. Kaniwa N, Saito Y.: Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J. Hum. Genet., 58: 317-326, 2013.
  7. Knights J, Chanda P, Sato Y, Kaniwa N, Saito Y, Ueno H, Zhang A, Ramanathan M.: Vertical integration of pharmacogenetics in population PK/PD modeling: A novel information theoretic method. CPT Pharmacometrics & Syst. Pharmacol. 2: e25, 2013.
  8. Fukuhara K, Ohno A, Ota Y, Senoo Y, Maekawa K, Okuda H, Kurihara M, Okuno A, Niida S, Saito Y, Takikawa O.: NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers. J. Clin. Biochem. Nutr., 52: 133-138, 2013.
  9. Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, Nakanishi H, Ikeda K, Arita M, Taguchi R, Okuno A, Mikawa R, Niida S, Takikawa O, Saito Y.: Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis., 12: 68, 2013.
  10. Hanatani T, Sai K, Tohkin M, Segawa K, Kimura M, Hori K, Kawakami J, Saito Y.: An algorithm for the identification of heparin-induced thrombocytopenia using a medical information database. J. Clin. Pharm. Ther., 38: 423-428, 2013.
  11. Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Takahashi A, Odaka Y, Okuyama M, Sawada JI, Sakamoto H, Yoshida T.: Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. J. Biosci. Bioeng., 116: 768-773, 2013.
  12. Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, Furuya H, Ikeda H, Takahashi Y, Muramatsu M, Tohkin M, Ozeki T, Mushiroda T, Kubo M, Kamatani N, Abe M, Yagami A, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Matsunaga K, Aihara M; Japan Pharmacogenomics Data Science Consortium.: Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics, 14: 1821-1831, 2013.
  13. Kaniwa N, Saito Y.: The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Ther. Adv. Drug Saf., 4: 246-253, 2013.
  14. 斎藤嘉朗, 前川京子, 田島陽子, 児玉進, 黒瀬光一: 市販後安全性確保に係るバイオマーカーと診断. レギュラトリーサイエンス学会誌, 3: 43-55, 2013.
  15. 斎藤嘉朗, 中村亮介, 黒瀬光一: 副作用バイオマーカーの探索と臨床応用研究の現状について. 臨床病理レビュー, 150: 27-33, 2013.
  16. 斎藤嘉朗, 前川京子, 齊藤公亮, 佐藤陽治, 鈴木孝昌: タンパク質・内在性代謝物バイオマーカーを利用した医薬品開発の活性化にむけて. 国立医薬品食品衛生研究所報告, 131: 20-24, 2013.
  17. 斎藤嘉朗, 佐井君江, 鹿庭なほ子, 田島陽子, 石川将己, 最上(西巻)知子, 前川京子: バイオマーカー探索研究とその臨床応用に向けて. 薬学雑誌, 133: 1373- 1379, 2013.
2012年
  1. Kurose K, Koizumi T, Nishikawa J, Maekawa K, Saito Y.: Quality requirements for genomic DNA preparations and storage conditions for a high-density oligonucleotide microarray. Biol Pharm Bull. 35: 1846-1848 (2012).
  2. Duan H, Yoshimura K, Kobayashi N, Sugiyama K, Sawada J, Saito Y, Morisseau C, Hammock BD, Akatsuka T.: Development of monoclonal antibodies to human microsomal epoxide hydrolase and analysis of "preneoplastic antigen"-like molecules. Toxicol Appl Pharmacol. 260: 17-26 (2012).
  3. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N, Fujiwara Y, Saito Y, Yamamoto H.: Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 35: 717-724 (2012).
  4. Sudo C, Maekawa K, Kaniwa N, Segawa K, Saito Y: Current status of drug-induced liver disease based on reports of adverse reactions to PMDA in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. in press.
  5. Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, Kato M, Wakeno M, Okugawa G, Kinoshita T, Kurosawa T, Hasegawa R, Saito Y.: Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res., 198: 424-429 (2012).
  6. Tada M, Ishii-Watabe A, Maekawa K, Fukushima-Uesaka H, Kurose K, Suzuki T, Kaniwa N, Sawada JI, Kawasaki N, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Okuda H, Hamaguchi T, Saito Y, Matsumura Y.: Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant. Immunogenetics. 64: 869-877 (2012).
  7. Maekawa K, Nishikawa J, Kaniwa N, Sugiyama E, Koizumi T, Kurose K, Tohkin M, Saito Y.: Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese. Drug Metab Pharmacokinet. 27: 447-450 (2012).
  8. Fukuhara K, Ohno A, Ota Y, Senoo Y, Maekawa K, Okuda H, Kurihara M, Okuno A, Niida S, Saito Y, Takikawa O.: NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers. J Clin Biochem Nutr. 52: 133-138 (2013).
  9. 斎藤嘉朗: 副作用の予測・提言を目指して, 薬剤学, 72: 95-100 (2012).
  10. 有田誠，斎藤嘉朗, 田口良，西島正弘: メタボローム新技術が切り拓くこれからの脂質バイオロジー研究. 実験医学, 30: 446-454 (2012).
  11. 門脇京子, 石黒昭博, 高松昭司, 斎藤嘉朗, 宇山佳明: 本邦の医薬品添付文書におけるゲノム薬理学関連情報およびその検査法の状況に関する調査・解析. レギュラトリーサイエンス学会誌. 2: 83-92 (2012).
  12. 黒瀬光一、斎藤嘉朗: ゲノム情報に基づいた副作用予測. 日本臨床(医薬品副作用学（第2版） －薬剤の安全使用アップデート－), 1026: 18-24 (2012).
  13. 斎藤嘉朗、須藤チエ: スティーブンス・ジョンソン症候群（SJS）および中毒性表皮壊死症（TEN）の発生状況と原因薬剤. 日本医事新報, 4613, 60-61 (2012).
  14. 斎藤嘉朗、前川京子、鹿庭なほ子: 日本人を対象にしたゲノム・メタボローム解析によるバイオマーカー探索. Pharmstage, 2012.9, 1-4 (2012).
  15. 斎藤嘉朗、前川京子、田島陽子、児玉進、黒瀬光一: 市販後安全性確保に係るバイオマーカーと診断. レギュラトリーサイエンス学会誌. 3: 43-55 (2013).
2011年
  1. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada J, Saijo N, Yoshida T, Tamura T.: Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel., J Thorac Oncol., 6: 132-138 (2011).
  2. Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, Kurose K, Sai K, Kaniwa N, Sawada JI, Kunitoh H, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Okuda H, Tamura T.: Genetic polymorphisms and haplotypes of POR encoding cytochrome P450 oxidoreductase in a Japanese population. Drug Metab. Pharmacokinet., 26: 107-116 (2011).
  3. Saeki M, Kurose K, Hasegawa R, Tohkin M.: Functional analysis of genetic variations in the 5'-flanking region of the human MDR1 gene. Mol. Genet. Metab., 102: 91-98 (2011).
  4. Hanioka N, Matsumoto K,Saito Y and Narimatsu S: Influence of CYP2C8*13 and CYP2C8*14 Alleles on Amiodarone N-Deethylation. Basic Clin. Pharmacol. Toxicol., 108: 359-362 (2011).
  5. Sai K. and Saito Y.: Ethnic differences in the metabolism and responses (toxicology and efficacy) of three anti-cancer drugs. Expert Opin. Drug Metab. Toxicol., 7: 967-988 (2011).
  6. Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Kamatani N, Ura T, Saito M, Muro K, Fuse N, Yoshino T, Doi T, Otsu A, Saijo N, Sawada JI, Okuda H, Matsumura Y. Drug Metab Pharmacokinet., 26: 646-658 (2011).
  7. Katori N, Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Yomota C, Kawanishi T, Nishimaki-Mogami T, Naito M, Sawada JI, Kunitoh H, Nokihara H, Sekine I, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Yamamoto N, Okuda H, Tamura T. J. Pharm Sci., 100: 4546-4559 (2011).
  8. 長谷川隆一, 岩崎甫: 重篤副作用を回避するためのファーマコゲノミクス研究. 薬学雑誌, 131: 237-238 (2011).
  9. 斎藤嘉朗: 抗がん剤の副作用回避のためのPharmacogenomics (PGx) 研究. 薬学雑誌, 131: 239-246 (2011).
  10. 鹿庭なほ子: 重症薬疹の発症と関連するバイオマーカーの探索研究. 薬学雑誌, 131: 255-262 (2011).
  11. 鹿庭なほ子: 重症薬疹の危険因子. 臨床免疫・アレルギー科, 56: 551-557 (2011).
  12. 須藤チエ, 東雄一郎, 前川京子, 鹿庭なほ子, 佐井君江, 斎藤嘉朗: 医薬品副作用自発報告からみる重篤副作用４種の最近の動向, 国立医薬品食品衛生研究所報告, 129: 111-117 (2011).
2010年
  1. Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 66: 95-105 (2010).
  2. Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.: Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics. 9: 695-704 (2010).
  3. Ikeda H., Takahashi Y., Yamazaki E., Fujiwara T., Kaniwa N., Saito Y., Aihara M., Kashiwagi M. and Muramatsu M.: HLA-class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 51: 297-300 (2010).
  4. Sugiyama E., Kaniwa N., Kim S.R., Hasegawa R.,Saito Y., Ueno H., Okusaka T., Ikeda M., Morizane C., Kondo S., Yamamoto N., Tamura T., Furuse J., Ishii H., Yoshida T., Saijo N. and Sawada J.: Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: Impact of genetic polymorphisms. Clin. Pharmacokinet., 49: 549-558 (2010).
  5. Hanioka N., Matsumoto K.,Saito Y. and Narimatsu S.: Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. Basic Clin. Pharmacol. Toxicol., 107: 565-569 (2010).
  6. Sai K.,Saito Y., Tatewaki N., Hosokawa M., Kaniwa N., Nishimaki-Mogami T., Naito M., Sawada J., Shirao K., Hamaguchi T., Yamamoto N., Kunitoh H., Tamura T., Yamada Y., Ohe Y., Yoshida T., Minami H., Ohtsu A., Matsumura Y., Saijo N., Okuda H.: Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br. J. Clin. Pharmacol., 70: 222-233 (2010).
  7. Maekawa K., Harakawa N., Yoshimura T., Kim S.R., Fujimura Y., Aohara F., Sai K., Katori N., Tohkin M., Naito M., Hasegawa R., Okuda H., Sawada J., Niwa T. and Saito Y.: CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs. Drug metab. Dispos., 38: 2100-2104, 2010.
  8. Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R.: Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab. Pharmacokinet., 25: 122-133 (2010).
  9. Ishii-Watabe A, Saito Y, Suzuki T, Tada M, Ukaji M, Maekawa K, Kurose K, Kaniwa N, Sawada JI, Kawasaki N, Yamaguchi T, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Hamaguchi T, Okuda H, Matsumura Y.: Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab. Pharmacokinet., 25: in press (2010).
  10. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.: HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 51: 2461-2465 (2010).
  11. K. Yamagishi, K. Yamamoto, Y. Mochizuki, T. Nakano, S. Yamada, H. Tokiwa, "Flexible ligand recognition of peroxisome proliferator-activated receptor-g (PPARg)", Bioorg. Med. Chem. Lett. 20, 3344 (2010).
  12. Y. Okiyama, T. Nakano, K. Yamashita, Y. Mochizuki, N. Taguchi, S. Tanaka, "Acceleration of fragment molecular orbital calculations with Cholesky decomposition approach", Chem. Phys. Lett. 490, 84-89 (2010).
  13. Y. Mochizuki, K. Yamashita, K. Fukuzawa, K. Takematsu, H. Watanabe, N. Taguchi, Y. Okiyama, M. Tsuboi, T. Nakano, S. Tanaka, "Large-scale FMO-MP3 calculations on the surface proteins of influenza virus, hemagglutinin (HA) and neuraminidase (NA)", Chem. Phys. Lett. 493, 346-352 (2010).
  14. H. Watanabe, Y. Okiyama, T. Nakano, S. Tanaka, “Incorporation of solvation effects into the fragment molecular orbital calculations with the Poisson-Boltzmann equation”, Chem. Phys. Lett. 500, 116-119 (2010).
  15. I. Kurisaki, K. Fukuzawa, T. Nakano, Y. Mochizuki, H. Watanabe, S. Tanaka, “Fragment molecular orbital (FMO) study on stabilization mechanism of neuro-oncological ventral antigen (NOVA)-RNA complex system”, J. Mol. Struct. (THEOCHEM) 962, 45-55 (2010).
  16. M. Sato, H. Yamataka, Y. Komeiji, Y. Mochizuki, T. Nakano, “Does Amination of Formaldehyde Proceed Through a Zwitterionic Intermediate in Water? Fragment Molecular Orbital Molecular Dynamics Simulations by Using Constraint Dynamics”, Chemistry - A European Journal, 16, 6430-6433 (2010).
  17. T. Ogawa, T. Nakano, “The Extended Universal Force Field (XUFF): Theory and Applications”, Chem-Bio. Info. J. 10, 111-133 (2010).
  18. 斎藤嘉朗, 奥田晴宏, 澤田純一: ファーマコゲノミクス解析 国立医薬品食品衛生研究所での１０年. ファルマシア, 46: 403-408 (2009).
  19. 斎藤嘉朗、杉山永見子, 長谷川隆一 : 一塩基多型（SNP）解析. ぶんせき, 239-245 (2010).
  20. 斎藤嘉朗、佐井君江、澤田純一:薬剤副作用に関する遺伝子解析. 日本臨床, 68 Suppl 8 :263-268 (2010).
2009年
  1. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J.: Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer, 100: 870-873 (2009).
  2. Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.: Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol, 27: 2261-2268 (2009).
  3. Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J.: Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica, 39: 140-147 (2009).
  4. Tatewaki N, Maekawa K, Katori N, Kurose K, Kaniwa N, Yamamoto N, Kunitoh H, Ohe Y, Nokihara H, Sekine I, Tamura T, Yoshida T, Saijo N, Saito Y, Sawada J.: Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population. Drug Metab Pharmacokinet., 24: 118-126 (2009).
  5. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim SR, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada JI, Yoshida T.: A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. Pharmacogenomics J. 9: 137-146 (2009)
  6. Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Sawada J.: Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos., 37: 272-276 (2009).
  7. Sai K., Minami H., Saito Y. and Sawada J.: Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment. Pharmacogenomics, Anticancer Drug Discovery, and Response (ed. F. Innocenti), Human Press, Totawa NJ, 2009, pp. 267-286.
  8. Sugiyama E, Lee SJ, Lee SS, Kim WY, Kim SR, Tohkin M, Hasegawa R, Okuda H, Kawamoto M, Kamatani N, Sawada J, Kaniwa N, Saito Y, Shin JG.: Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet. 24: 553-556 (2009).
  9. Fukushima-Uesaka H, Saito Y, Maekawa K, Kurose K, Sugiyama E, Katori N, Kaniwa N, Hasegawa R, Hamaguchi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Yamamoto N, Nokihara H, Kunitoh H, Ohe Y, Tamura T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Matsumura Y, Okuda H, Sawada J.: Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet. 24: 565-574 (2009).
  10. Y. Komeiji, T. Ishikawa, Y. Mochizuki, H. Yamataka, T. Nakano, “Fragment Molecular Orbital method-based Molecular Dynamics (FMO-MD) as a simulator for chemical reactions in explicit solvation”, J. Comput. Chem. 30, 40-50 (2009).
  11. Y. Komeiji, Y. Mochizuki, T. Nakano, and D. G. Fedorov, “Fragment Molecular Orbital-based Molecular Dynamics (FMO-MD), a quantum simulation tool for large molecular systems”, J. Mol. Struct. (Theochem), 898, 2-7 (2009).
  12. T. Fujita, K. Fukuzawa, Y. Mochizuki, T. Nakano, S. Tanaka, "Accuracy of fragmentation in ab initio calculations of hydrated sodium cation", Chem. Phys. Lett. 478 295-300 (2009).
  13. T. Watanabe, Y. Inadomi, H. Umeda, K. Fukuzawa, S. Tanaka, T. Nakano, U. Nagashima, "Fragment Molecular Orbital (FMO) and FMO-MO Calculations of DNA: Accuracy Validation of Energy and Interfragment Interaction Energy", J. Comp. Theor. Nanosci. 6, 1328-1337 (2009).
  14. K. Takematsu, K. Fukuzawa, K. Omagari, S. Nakajima, K. Nakajima, Y. Mochizuki, T. Nakano, H. Watanabe, S. Tanaka, "Possibility of mutation prediction of influenza hemagglutinin by combination of hemadsorption experiment and quantum chemical calculation for antibody binding", J. Phys. Chem. B 113, 4991-4994 (2009).
  15. N. Taguchi, Y. Mochizuki, T. Nakano, S. Amari, K. Fukuzawa, T. Ishikawa, M. Sakurai, S. Tanaka, "Fragment Molecular Orbital Calculations on Red Fluorescent Proteins (DsRed and mFruits)", J. Phys. Chem. B 113, 1153-1161 (2009).
  16. Y. Okiyama, H. Watanabe, K. Fukuzawa, T. Nakano, Y. Mochizuki, T. Ishikawa, K. Ebina, S. Tanaka, "Application of the fragment molecular orbital method for determination of atomic charges on polypeptides. II. Towards an improvement of force fields used for classical molecular dynamics simulations", Chem. Phys. Lett. 467, 417-423 (2009).
  17. 斎藤嘉朗, 澤田純一: ファーマコゲノミクス. 日本臨床, 67: 1175-1179 (2009).
  18. 前川京子, 斎藤嘉朗, 佐井君江, 澤田純一: 医薬品の応答性に関連する遺伝子多型 -抗血栓薬を中心に-. 血栓止血誌, 20: 27-36 (2009).
  19. 斎藤嘉朗, 前川京子, 澤田純一: 遺伝子多型解析. 日本臨床, 67, Suppl.1: 186-191 (2009).
2008年
  1. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 9: 1617-1622 (2008).
  2. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, Saijo N, Ozawa S, Sawada J.: Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet., 23:379-384 (2008).
  3. Sai K., Saito Y., Itoda M., Fukushima-Uesaka H., Ozawa S., Kurose K., Kaniwa N., Kawamoto M., Kamatani N., Shirao K., Yamamoto N., Hamaguchi T., Kunitoh H., Ohe Y., Yamada Y., Tamura T., Yoshida T., Minami H., Matsumura Y., Ohtsu A., Saijo N., J. Sawada: Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug. Metab. Pharmacokinet., 23: 139-147 (2008).
  4. Sai K., Saito Y., Fukushima-Uesaka H., Kurose K., Kaniwa N., Kamatani N., Shirao K., Yamamoto N., Hamaguchi T., Kunitoh H., Ohe Y., Tamura T., Yamada Y., Minami H., Ohtsu A., Yoshida T., Saijo N., Sawada J.: Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother. Pharmacol., 62: 529-537 (2008).
  5. Saeki M, Kurose K, Tohkin M, Hasegawa R.: Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem. Pharmacol., 76: 531-542 (2008).
  6. Kurose K, Saeki M, Tohkin M, Hasegawa R.: Thyroid hormone receptor mediates human MDR1 gene expression-Identification of the response region essential for gene expression. Arch Biochem Biophys., 474: 82-90 (2008).
  7. M. Ito, K. Fukuzawa, Y. Mochizuki, T. Nakano, S. Tanaka, “Ab Initio Fragment Molecular Orbital Study of Molecular Interactions between Liganded Retinoid X Receptor and Its Coactivator; Part II: Influence of Mutations in Transcriptional Activation Function 2 Activating Domain Core on the Molecular Interactions”, J. Phys. Chem. A 112, 1986-1998 (2008).
  8. M. Sato, H. Yamataka, Y. Komeiji, Y. Mochizuki, T. Ishikawa, T. Nakano, “How Does an SN2 Reaction Take Place in Solution? Full Ab Initio MD Simulations for the Hydrolysis of the Methyl Diazonium Ion”, J. Am. Chem. Soc. 130, 2396-2397 (2008).
  9. K. Koyano and T. Nakano, “Interaction of HIV-1 aspartic protease with its inhibitor, by molecular dynamics and ab initio fragment molecular orbital method”, J. Synchrotron Rad. 15, 239-242 (2008).
  10. Y. Mochizuki, K. Yamashita, T. Murase, T. Nakano, K. Fukuzawa, K. Takematsu, H. Watanabe, S. Tanaka, “Large scale FMO-MP2 calculations on a massively parallel-vector computer”, Chem. Phys. Lett. 457, 396-403 (2008).
  11. T. Harada, K. Yamagishi, T. Nakano, K. Kitaura, H. Tokiwa, "Ab initio fragment molecular orbital study of ligand binding to human progesterone receptor ligand-binding domain", Naunyn-Schmiedeberg's Arch. Pharmac. 377, 607-615 (2008).
  12. M. Ito, K. Fukuzawa, T. Ishikawa, Y. Mochizuki, T. Nakano, and S. Tanaka, “Ab Initio Fragment Molecular Orbital Study of Molecular Interactions in Liganded Retinoid X Receptor: Specification of Residues Associated with Ligand Inducible Information Transmission”, J. Phys. Chem. B, 112, 12081-12094 (2008).
  13. T. Ishikawa, Y. Mochizuki, S. Amari, T. Nakano, S. Tanaka, K. Tanaka, “An application of fragment interaction analysis based on local MP2”, Chem. Phys. Lett. 463, 189-194 (2008).
2007年
  1. Saeki M, Saito Y, Sai K, Maekawa K, Kaniwa N, Sawada J, Kawamoto M, Saito A, Kamatani N (2007) A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers. Clin Chem. 2007, 53, 356-358.
  2. Hasegawa R, Hirata-Koizumi M, Dourson M, Parker A, Hirose A, Nakai S, Kamata E, Ema M (2007) Pediatric susceptibility to 18 industrial chemicals: A comparative analysis of newborn with young animals. Regul Toxicol Pharmacol, 47, 296-307.
  3. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharcokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol, 25, 32-42.
  4. Fukushima-Uesaka H, Saito Y, Tohkin M, Maekawa K, Hasegawa R, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Kajio H, Kuzuya N, Yasuda K, Sawada J (2007) Genetic Variations and Haplotype Structures of the ABC Transporter Gene ABCC1 in a Japanese Population. Drug Metab Pharmacokinet, 22, 48-60.
  5. Hirata-Koizumi M, Saito M, Miyake S, Hasegawa R (2007) Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA. J Clin Pharm Ther, 32, 177-185.
  6. 長谷川隆一、齋藤充生 (2007) 海外で発売中止となった医薬品の国内状況. 日本薬理学雑誌, 129, 227.
  7. 齋藤充生，平田睦子，浦野勉，三宅真二，長谷川隆一 (2007) スタチン系薬剤の他剤との臨床および非臨床薬物動態学的相互作用の比較. 医療薬学, 33, 291-300.
  8. Choi DH, Katakura Y, Matsuda R, Hayashi Y, Hirobe M, Goda Y, Ninomiya K, Shioya S (2007) Validation of a method for predicting the precision, limit of detection and range of quantitation in competitive ELISA, Anal Sci, 23, 215-218.
  9. 田中秀和，林 譲，矢島毅彦 (2007) 薬局の持っている情報はどのように利用できるか？第1回 薬局情報の特徴，表示と解釈. レシピ, 6, 73-76.
  10. 岩木和夫，竹内尚子，林 譲，矢島毅彦 (2007) 薬剤師が看る国民の健康状態～ヘルスヴィジランス～ 第2回 東京近辺におけるインフルエンザの感染経路と伝播速度. 薬局, 58, 113-116.
  11. 林 譲，竹内尚子，岩木和夫，矢島毅彦 (2007) 薬剤師が看る国民の健康状態～ヘルスヴィジランス～ 第3回 これでわかる相関係数と相互相関関数. 薬局, 58, 493-498.
  12. Mochizuki Y, Tanaka K, Yamashita K, Ishikawa T, Nakano T, Amari S, Segawa K, Murase T, Tokiwa H, Sakurai M (2007) Parallelized integral-direct CIS(D) calculations with multilayer fragment molecular orbital scheme, Theor Chem Acc, 117, 541-553.
  13. Mochizuki Y, Nakano T, Amari S, Ishikawa T, Tanaka K, Sakurai M, Tanaka S (2007) Fragment molecular orbital calculations on red fluorescent protein (DsRed), Chem Phys Lett, 433, 360-367.
  14. Mochizuki Y, Komeiji Y, Ishikawa T, Nakano T, Yamataka H (2007) A fully quantum mechanical simulation study on the lowest n-p* state of hydrated formaldehyde, Chem Phys Lett, 437, 66-72.
  15. Ito M, Fukuzawa K, Mochizuki Y, Nakano T, Tanaka S (2007) Ab Initio Fragment Molecular Orbital Study of Molecular Interactions between Liganded Retinoid X Receptor and Its Coactivator: Roles of Helix 12 in the Coactivator Binding Mechanism, J Phys Chem B, 111, 3525-3533.
  16. 前田紘輔, A. Schug, 渡邉博文, 福澤薫, 望月祐志, 中野達也, 田中成典 (2007) エストロゲン受容体のアミノ酸変異によるエストラジオール結合エネルギーの変化, J Comput Chem Jpn, 6, 33-46.
  17. 中野達也, 望月祐志, 甘利真司，小林将人，福澤薫，田中成典, “フラグメント分子軌道法に基づいた生体巨大分子の電子状態計算の現状と今後の展望”, J. Comput. Chem. Jpn. 6, 173-184 (2007).
  18. 福澤薫, 中野達也, 加藤昭史, 望月祐志, 田中成典, “フラグメント分子軌道法による生体高分子の応用計算”, J. Comput. Chem. Jpn. 6, 185-198 (2007).
2006年
  1. 上野秀樹、鹿庭なほ子 (2006) ゲムシタビンンの薬理ゲノム学－シチジンデアミナーゼの遺伝子多型, 4, 47-51.
  2. Kurose K, Ikeda S, Koyano S, Tohkin M, Hasegawa R, Sawada J (2006) Identification of regulatory sites in the human PXR (NR1I2) promoter region. Mol Cell Biochem, 281, 35-43.
  3. Hamamura M, Hirose A, Kamata E, Katoku K, Kuwasaki E, Oshikawa T, Nakahara Y, Ema M, Hasegawa R (2006) Semi-quantitative immunohistochemical analysis of male rat-specific a2u-globulin accumulation for chemical toxicity evaluation. J Toxicol Sci, 31, 35-47.
  4. Takahashi M, Hirata-Koizumi M, Nishimura N, Ito Y, Sunaga M, Fujii S, Kamata E, Hasegawa R, Ema M (2006) Susceptibility of newborn rats to 3-ethylphenol and 4-ethylphenol compared with that of young rats. Congenit Anom, 46, 26-33.
  5. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Shirao K, Tamura T, Yamamoto N, Kunitoh H, Hamaguchi T, Yoshida T, Kubota K, Ohtsu A, Muto M, Minami H, Saijo N, Kamatani N, Sawada J (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J, 6, 63-75.
  6. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract, 72, 148-154.
  7. Maekawa K, Itoda M, Sai K, Saito Y, Kaniwa N, Shirao K, Hamaguchi T, Kunitoh H, Yamamoto N, Tamura T, Minami H, Kubota K, Ohtsu A, Yoshida T, Saijo N, Kamatani N, Ozawa S, Sawada J (2006) Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. Drug Metab Pharmacokinet, 21, 109-121.
  8. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T , Saito Y, Sawada J (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics, 16, 497-514
  9. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Morizane C, Yamamoto N, Ikeda M, Yoshida T, Minami H, Furuse J, Ishii H, Saijo N, Kamatani N, Ozawa S, Sawada J (2006) Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet, 21, 248-256.
  10. 松本真理子, 高橋美加, 平田睦子, 広瀬明彦, 鎌田栄一, 長谷川隆一, 江馬 眞 (2006) OECD高生産量化学物質点検プログラム: 第18回初期評価会議までの概要, 化学生物総合管理学会誌, 2, 104-134.
  11. 長谷川隆一 (2006) 有害事象に関与する薬物動態相互作用. ファームステージ, 6(6), 43-48.
  12. Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, Ozawa S, Aoyagi N, Kamatani N, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Yoshida T, Minami H, Saijo N, Katori N, Sawada J. (2006) Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther, 80(2):179-191.
  13. Sai K, Itoda M, Saito Y, Kurose K, Katori N, Kaniwa N, Komamura K, Kotake T, Morishita H, Tomoike H, Kamakura S, Kitakaze M, Tamura T, Yamamoto N, Kunitoh H, Yamada Y, Ohe Y, Shimada Y, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kamatani N, Ozawa S, Sawada J. (2006) Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences. Ann Hum Genet, 70(Pt 5):605-622.
  14. Kim SR, Ozawa S, Saito Y, Kurose K, Kaniwa N, Kamatani N, Hamaguchi T, Shirao K, Muto M, Ohtsu A, Yoshida T, Matsumura Y, Saijo N, Sawada J (2006) Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS). Drug Metab Pharmacokinet, 21, 509-516
  15. 齋藤充生、平田睦子、三宅真二、長谷川隆一 (2006) 日米欧3極における新有効成分医薬品の2005年承認状況と過去4年間の共通承認並びに先行承認の解析. 衛研報告, 124, 80-82.
  16. 平田睦子、齋藤充生、三宅真二、長谷川隆一 (2006) 医薬品の環境リスク評価に関する研究：環境中への排泄形態. 衛研報告, 124, 83-86.
  17. 頭金正博 (2006) ファルネソイドＸ受容体を介した胆汁酸による生理機能の制御. 臨床化学, 35, 136-143.
2005年
  1. Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how this is reflected in package inserts of Japan. J Clin Pharm Ther, 30, 21-37.
  2. 高橋美加、平田睦子、松本真理子、広瀬明彦、鎌田栄一、長谷川隆一、江馬眞 (2005) OECD化学物質対策の動向（第6報）第14回OECD高生産量化学物質初期評価会議（2002年パリ）, 化学生物総合管理, 1, 46-55.
  3. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an Africa-American. Drug Metab Dispos, 33, 458-465.
  4. Hirata-Koizumi M, Kusuoka O, Nishimura N, Wada H, Ogata H, Fukuda N, Ito Y, Kamata E, Ema M, Hasegawa R (2005) Susceptibility of newborn rats to hepatotoxicity of 1,3-dibromopropane and 1,1,2,2-tetrabromomethane, compared with young rats. J Toxicol Sci, 30, 29-42.
  5. Nakajima Y, Saito Y, Shiseki K, Fukushima-Uesaka H, Hasegawa R, Ozawa S, Sugai K, Katoh M, Saitoh O, Ohnuma T, Kawai M, Ohtsuki T, Suzuki C, Minami N, Kimura H, Goto Y, Kamatani N, Kaniwa N, Sawada J (2005) Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol, 60, 25-34.
  6. Kurose K, Tohkin M, Hasegawa R (2005) Transcription factor NF2d9 (LBP-1a) interacts with the positive regulatory element for the xenobiotic responsive element. Biochim Biophys Acta, 1727, 141-144.
  7. Saeki M, Saito Y, Jinno H, Sai K, Kaniwa N, S. Ozawa S, Kawamoto M, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kamatani N, Sawada J (2005) Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet, 20, 85-90.
  8. Koyano S, Saito Y, Sai K, Kurose K, Ozawa S, Nakajima T, Matsumoto K, Saito H, Shirao K, Yoshida T, Minami H, Ohtsu A, Saijo N, Sawada J (2005) Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population. Drug Metab Pharmacokinet, 20, 79-84.
  9. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res, 11, 2620-2624.
  10. Kurose K, Koyano S, Ikeda S, Tohkin M, Hasegawa R, Sawada J (2005) 5' diversity of human hepatic PXR (NR1I2) transcripts and identification of the major transcription initiation site. Mol Cell Biochem, 273, 79-85.
2004年
  1. Koyano S, Kurose K, Saito Y, Ozawa S, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Nakajima T, Matsumoto K, Akasawa A, Saito H, Sawada J (2004) Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos, 32, 149-154.
  2. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T Kurose, K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population, Hum Mut, 23, 100.
  3. Fukuda N, Ito Y, Yamaguchi M, Mitsumori K, Koizumi M, Hasegawa R, Kamata E, Ema M (2004) Unexpected nephrotoxicity induced by tetrabromobisphenol A in newborn rats. Toxicol Lett, 150, 145-155.
  4. 鹿庭なほ子，青柳伸男 (2004) 局所皮膚適用製剤の後発医薬品のための生物学的同等性試験ガイドラインについて. 医薬品研究, 35, 212-222.
  5. Umemura T, Kitamura Y, Kanki K, Maruyama S, Okazaki K, Imazawa T, Nishimura T, Hasegawa R, Nishikawa A, Hirose M (2004) Dose-related changes of oxidative stress and cell proliferation in kidneys of male and female F344 rats exposed to potassium bromate. Cancer Sci, 95, 393-398.
  6. 長谷川隆一 (2004) 医薬品の適正使用のための基盤的研究. 医薬品研究, 35, 265-279.
  7. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura K, Kitakaze M, Kitamura Y, Kamatani N , Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther, 75, 501-515.
  8. Hasegawa R, Koizumi M, Hirose A (2004) Principles of risk assessment for determining the safety of chemicals: Recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate. Congenit Anom ( Kyoto ), 44, 51-59.
  9. 浦野 勉、小泉睦子、齋藤充生、長谷川隆一 (2004) 海外で安全性のために販売中止となった医薬品の国内での安全対策. 医薬品研究, 35, 453-460.
  10. 高橋美加、小泉睦子、松本真理子、広瀬明彦、鎌田栄一、長谷川隆一、江馬 眞 (2004) OECD化学物質対策の動向（第5報）第12回及び第13回OECD高生産量化学物質初期評価会議（2001年）. 衛研報告, 122, 37-42.
  11. Takahashi M, Ogata H, Izumi H, Yamashita K, Takechi M, Hirata-Koizumi M, Kamata E, Hasegawa R, Ema M (2004) Comparative study of toxicity of 2,4,6-trinitrophenol (picric acid) in newborn and young rats. Congenit Anom ( Kyoto ), 44, 204-214.
  12. Hirose A, Hasegawa R, Takahashi M, Nishikawa A, Ema M (2004) Revision and establishment of Japanese drinking water quality guidelines for di(ethylhexyl) phthalate, toluene and vinyl chloride - Differences from the latest WHO guideline drafts -. J Toxicol Sci, 29, 535-553.
2003年
  1. 長谷川隆一 (2003) 化学物質の安全性評価の現状. 塩ビ食品衛生協議会会報, 142, 5-18.
  2. Connelly J, Osterberg RE, Tucker ML, Hasegawa R (2003) ICH Guideline Residual Solvents: Update. Pharmeuropa, 15, 365-372.
  3. Koizumi M, Noda A, Ito Y, Furukawa M, Fujii M, Kamata E, Ema M, Hasegawa R (2003) Higher susceptibility of newborn than young rats to 3-methylphenol. J Toxicol Sci, 28, 59-70.
  4. 広瀬明彦、江馬 眞、鎌田栄一、小泉睦子、長谷川隆一 (2003) ビスフェノールAの内分泌かく乱作用のヒトへの健康影響評価. 日本食品化学学会誌, 10, 1-12.
  5. Umemura T, Kai S, Hasegawa R, Kanki K, Kitamura Y, Nishikawa A, Hirose M (2003) Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine-induced hepato- and cholangio-carcinogenesis in mice by green tea infusion. Carcinogenesis, 24, 1105-1109.
  6. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J (2003) Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics, 13, 741-754.
  7. Oka T, Adati N, Shinkai T, Sakuma K, Nishimura T, Kurose K (2003) Bisphenol A Induces Apoptosis in Central Neural Cells During Early Development of Xenopus laevis. Biochem Biophys Res Commun, 312, 877-882.
  8. Saeki M, Saito Y, Jinno H, Tohkin M, Kurose K, Kaniwa N, Komamura K, Ueno K, Kamakura S, Kitakaze M, Ozawa S, Sawada J (2003) Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin Chem, 49, 1182-1185.
  9. Ikeda S, Kurose K, Ozawa S, Sai K, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Tomoike H, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Saito Y, Sawada J (2003) Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population. Drug Metab Pharmacokinet, 18, 413-418.
2002年
  1. 小嶋茂雄、島田弘康、橋本正晴、苗代一郎、中島芳文、門田利人、三宅行雄、森田 健、若田明裕、竹内正紀、酒井喜代志、鈴木専二、松澤利明、奥田秀毅、井上 達、林 真、長谷川隆一、奥田晴宏、高田幸一 (2002) 原薬及び製剤中の不純物の安全性確認に関するQ&A. 医薬品研究, 33, 17-27.
  2. 廣瀬明彦、西川秋佳、江馬 真、紅林秀雄、山田雅巳、長谷川隆一 (2002) メチル-tert-ブチルエーテル(MTBE)の毒性情報. 水環境学会誌, 25, 491-496.
  3. 小泉睦子、大野泰男、広瀬雅雄、江馬 眞、井上 達、長谷川隆一 (2002) DINPの毒性評価と耐容1日摂取量の算定. 日本食品化学学会誌, 9, 39-45.
  4. Koizumi M, Nishimura N, Enami T, Sunaga M, Horikawa H, Kamata E, Hasegawa R (2002) Comparative toxicity study of 3-aminophenol in newborn and young rats. J Toxicol Sci, 27, 411-421.
  5. Koyano S, Kurose K, Ozawa S, Saeki M, Nakajima Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Nakajima T, Saito H, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Saito Y, Sawada J (2002) Eleven novel single nucleotide polymorphisms in the NR112 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metabol Pharmacokinet, 17, SNP27 (561)-SNP31 (565).
  6. 鹿庭なほ子 (2002) 溶出試験の変動要因と適格性評価. Pharm Tech Japan, 18, 1865-1871.
  7. Morihara M, Aoyagi N, Kaniwa N, Katori N, Kojim S. (2002) Hydrodynamic flows around tablets in different pharmacopeial dissolution tests. Drug Dev Ind Pharm, 28, 655-662.
  8. Kaniwa N (2002) Japanese Perspectives on Pharmaceutical Product Release Rate Testing. Drug Inform J, 36, 407-415.
  9. Sai K, Kaniwa N, Ozawa S, Sawada J (2002) An Analytical Method for Irinotecan (CPT-11) and its Metabolites using a High-performance Liquid Chromatography: Parallel Detection with Fluorescence and Mass Spectrometry. Biomed Chromat, 16, 209-218.
  10. 頭金正博 (2002) LXRとFXRによる脂質代謝制御. Molecular Medicine, 39, 294-300.
  11. 頭金正博, Sinal C, 宮田昌明, Gonzalez F (2002) 核内受容体FXR/BARによるCyp7aの発現調節機構. 生化学, 73, 1489.

書籍

  1. 長谷川隆一：トキシコロジー、日本トキシコロジー学会教育委員会編集（共著）、朝倉書店、東京、2002.
  2. 鹿庭なほ子：医薬品の品質確保、奥田秀毅、小嶋茂雄、綱川延孝編（共著）、LIC、東京、2002.
  3. 長谷川隆一：トキシコロジー用語事典、日本トキシコロジー学会編集（共著）、じほう、東京、2003.
  4. 鹿庭なほ子：医薬品の臨床薬物動態試験（共著）、じほう、東京、2003.
  5. 鹿庭なほ子：医薬品の分析法バリデーション、林純薬工業、大阪、2003.
  6. 長谷川隆一：医薬品の安全性 長尾 拓 編（共著）、南山堂、東京、2004.

<< 前のページに戻る